文献速递流行病学与生物统计临床试验与 GCP

抗抑郁药治疗成人疼痛的疗效、安全性和耐受性:系统综述的概览

Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews.
PubMed 文献 · BMJ · 2023-02-01

该概览纳入26篇系统综述(156项独特试验,超过25000名受试者),评估八类抗抑郁药对22种疼痛状况的疗效、安全性和耐受性。42项比较中仅11项显示有效,其中4项为中等确定性证据:SNRIs对背痛、术后疼痛、神经病理性疼痛和纤维肌痛有效;其余31项比较中5项无效、26项证据不确定。未发现任何高强度确定性证据。

要点

  • 42项比较中11项显示抗抑郁药有效,其中7项涉及SNRIs。
  • SNRIs对背痛、术后疼痛、神经病理性疼痛和纤维肌痛有中等确定性证据支持。
  • 其余31项比较中5项无效、26项证据不确定,无高强度确定性证据。

核心结论

  • 42项比较中11项发现抗抑郁药有效,其中7项涉及SNRIs;其余31项中5项无效、26项证据不确定。
  • 作者认为处方抗抑郁药治疗疼痛时需要更细致的方法。

研究设计与样本

  • 系统综述的概览,检索PubMed、Embase、PsycINFO和Cochrane中央对照试验注册库,从建库至2022年6月20日。
  • 纳入比较任何抗抑郁药与安慰剂治疗成人任何疼痛状况的系统综述。
  • 共纳入26篇综述(156项独特试验,超过25000名受试者),涵盖八类抗抑郁药和22种疼痛状况(42项不同比较)。
  • 主要结局为疼痛(头痛障碍为头痛频率),连续结局转换为0(无痛)至100(最痛)量表,以均数差(95%CI)表示;二分类结局以风险比(95%CI)表示。
  • 证据确定性采用GRADE框架评估。

主要发现

  • 背痛:SNRIs均数差-5.3(95%CI -7.3至-3.3),中等确定性证据。
  • 术后疼痛:SNRIs均数差-7.3(95%CI -12.9至-1.7),中等确定性证据。
  • 神经病理性疼痛:SNRIs均数差-6.8(95%CI -8.7至-4.8),中等确定性证据。
  • 纤维肌痛:SNRIs风险比1.4(95%CI 1.3至1.6),中等确定性证据。
  • 42项比较中11项(9种状况)显示抗抑郁药有效,其余31项中5项无效、26项证据不确定;无任何状况有高强度确定性证据。

临床怎么用

  • 作者认为处方抗抑郁药治疗疼痛时需要更细致的方法。
  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide a comprehensive overview of the efficacy, safety, and tolerability of antidepressants for pain according to condition. DESIGN: Overview of systematic reviews. DATA SOURCES: PubMed, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials from inception to 20 June 2022. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Systematic reviews comparing any antidepressant with placebo for any pain condition in adults. DATA EXTRACTION AND SYNTHESIS: Two reviewers independently extracted data. The main outcome measure was pain; for headache disorders it was frequency of headaches. Continuous pain outcomes were converted into a scale of 0 (no pain) to 100 (worst pain) and were presented as mean differences (95% confidence intervals). Dichotomous outcomes were presented as risk ratios (95% confidence intervals). Data were extracted from the time point closest to the end of treatment. When end of treatment was too variable across trials in a review, data were extracted from the outcome or time point with the largest number of trials and participants. Secondary outcomes were safety and tolerability (withdrawals because of adverse events). Findings were classified from each comparison as efficacious, not efficacious, or inconclusive. Certainty of evidence was assessed with the grading of recommendations assessment, development, and evaluation framework. RESULTS: 26 reviews (156 unique trials and >25 000 participants) were included. These reviews reported on the efficacy of eight antidepressant classes covering 22 pain conditions (42 distinct comparisons). No review provided high certainty evidence on the efficacy of antidepressants for pain for any condition. 11 comparisons (nine conditions) were found where antidepressants were efficacious, four with moderate certainty evidence: serotonin-norepinephrine reuptake inhibitors (SNRIs) for back pain (mean difference -5.3, 95% confidence interval -7.3 to -3.3), postoperative pain (-7.3, -12.9 to -1.7), neuropathic pain (-6.8, -8.7 to -4.8), and fibromyalgia (risk ratio 1.4, 95% confidence interval 1.3 to 1.6). For the other 31 comparisons, antidepressants were either not efficacious (five comparisons) or the evidence was inconclusive (26 comparisons). CONCLUSIONS: Evidence of efficacy of antidepressants was found in 11 of the 42 comparisons included in this overview of systematic reviews-seven of the 11 comparisons investigated the efficacy of SNRIs. For the other 31 comparisons, antidepressants were either inefficacious or evidence on efficacy was inconclusive. The findings suggest that a more nuanced approach is needed when prescribing antidepressants for pain conditions. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42022311073.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Ferreira GE, Abdel-Shaheed C, Underwood M, et al. Efficacy, safety, and tolerability of antidepressants for pain in adults: overview of systematic reviews. BMJ. 2023. PMID: 36725015. doi:10.1136/bmj-2022-072415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。